Published in Curr Respir Med Rev on March 28, 2016
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02
ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med (2002) 31.79
Psychophysical bases of perceived exertion. Med Sci Sports Exerc (1982) 30.13
An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med (2011) 22.39
American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med (2000) 12.71
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med (2014) 10.62
A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med (2014) 9.40
Cyclophosphamide versus placebo in scleroderma lung disease. N Engl J Med (2006) 9.17
An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med (2013) 6.82
Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2007) 6.71
Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. N Engl J Med (2012) 6.51
Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med (2012) 5.33
The measurement of dyspnea. Contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest (1984) 5.19
A placebo-controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2012) 4.81
Predicting survival in idiopathic pulmonary fibrosis: scoring system and survival model. Am J Respir Crit Care Med (2001) 4.39
Interstitial lung disease in systemic sclerosis: a simple staging system. Am J Respir Crit Care Med (2008) 3.19
Fibrotic idiopathic interstitial pneumonia: the prognostic value of longitudinal functional trends. Am J Respir Crit Care Med (2003) 3.07
Histopathologic subsets of fibrosing alveolitis in patients with systemic sclerosis and their relationship to outcome. Am J Respir Crit Care Med (2002) 3.06
Rheumatoid arthritis-interstitial lung disease-associated mortality. Am J Respir Crit Care Med (2010) 3.05
Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax (2003) 2.93
Idiopathic pulmonary fibrosis: a composite physiologic index derived from disease extent observed by computed tomography. Am J Respir Crit Care Med (2003) 2.78
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database. Ann Rheum Dis (2010) 2.71
Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med (2011) 2.62
Validation of a new dyspnea measure: the UCSD Shortness of Breath Questionnaire. University of California, San Diego. Chest (1998) 2.57
Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2011) 2.54
Randomized, prospective, placebo-controlled trial of bosentan in interstitial lung disease secondary to systemic sclerosis. Arthritis Rheum (2010) 2.37
Idiopathic pulmonary fibrosis: prognostic value of changes in physiology and six-minute-walk test. Am J Respir Crit Care Med (2006) 2.37
Thalidomide for the treatment of cough in idiopathic pulmonary fibrosis: a randomized trial. Ann Intern Med (2012) 2.36
Assessment of health-related quality of life in patients with interstitial lung disease. Chest (1999) 2.21
The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time. Arthritis Rheum (1997) 2.21
The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med (2009) 2.18
CT analysis of the effect of pirfenidone in patients with idiopathic pulmonary fibrosis. Eur J Radiol (2012) 2.15
Severe restrictive lung disease in systemic sclerosis. Arthritis Rheum (1994) 2.11
Prognostic value of desaturation during a 6-minute walk test in idiopathic interstitial pneumonia. Am J Respir Crit Care Med (2003) 2.10
A comparison of the visual analogue scale and modified Borg scale for the measurement of dyspnoea during exercise. Clin Sci (Lond) (1989) 2.06
The Leicester Cough Monitor: preliminary validation of an automated cough detection system in chronic cough. Eur Respir J (2008) 2.01
Induced sputum inflammatory mediator concentrations in chronic cough. Am J Respir Crit Care Med (2003) 1.98
High-resolution computed tomography in idiopathic pulmonary fibrosis: diagnosis and prognosis. Am J Respir Crit Care Med (2005) 1.90
Evaluation of a cough-specific quality-of-life questionnaire. Chest (2002) 1.89
Six-minute walk, maximal exercise tests: reproducibility in fibrotic interstitial pneumonia. Am J Respir Crit Care Med (2005) 1.86
Computed tomography findings in pathological usual interstitial pneumonia: relationship to survival. Am J Respir Crit Care Med (2007) 1.85
Limitations to the 6-minute walk test in interstitial lung disease and pulmonary hypertension in scleroderma. J Rheumatol (2009) 1.78
Predicting survival across chronic interstitial lung disease: the ILD-GAP model. Chest (2014) 1.72
Validity of two new patient-reported outcome measures in systemic sclerosis: Patient-Reported Outcomes Measurement Information System 29-item Health Profile and Functional Assessment of Chronic Illness Therapy-Dyspnea short form. Arthritis Care Res (Hoboken) (2011) 1.67
Idiopathic pulmonary fibrosis: physiologic tests, quantitative CT indexes, and CT visual scores as predictors of mortality. Radiology (2008) 1.66
Hot of the breath: mortality as a primary end-point in IPF treatment trials: the best is the enemy of the good. Thorax (2012) 1.65
A clinical, radiographic, and physiologic scoring system for the longitudinal assessment of patients with idiopathic pulmonary fibrosis. Am Rev Respir Dis (1986) 1.65
Analyses of efficacy end points in a controlled trial of interferon-gamma1b for idiopathic pulmonary fibrosis. Chest (2005) 1.60
Development of self-administered versions of modified baseline and transition dyspnea indexes in COPD. COPD (2004) 1.58
High-resolution CT findings in fibrotic idiopathic interstitial pneumonias with little honeycombing: serial changes and prognostic implications. AJR Am J Roentgenol (2012) 1.53
Quantification of dyspnoea using descriptors: development and initial testing of the Dyspnoea-12. Thorax (2009) 1.50
The six-minute walk test using forehead oximetry is reliable in the assessment of scleroderma lung disease. Respirology (2012) 1.49
Dyspnoea and comorbidity contribute to anxiety and depression in interstitial lung disease. Respirology (2014) 1.44
Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the Scleroderma Lung Study. Chest (2012) 1.44
Health-related quality of life among patients with idiopathic pulmonary fibrosis. Chest (2005) 1.36
The impact of cardiopulmonary manifestations on the mortality of SSc: a systematic review and meta-analysis of observational studies. Rheumatology (Oxford) (2012) 1.33
Pulmonary function in idiopathic pulmonary fibrosis and referral for lung transplantation. Am J Respir Crit Care Med (2001) 1.29
Interobserver variability in the CT assessment of honeycombing in the lungs. Radiology (2012) 1.26
Diagnosis and treatment of connective tissue disease-associated interstitial lung disease. Chest (2013) 1.24
Review series: Aspects of interstitial lung disease: connective tissue disease-associated interstitial lung disease: how does it differ from IPF? How should the clinical approach differ? Chron Respir Dis (2011) 1.23
Cough frequency, cough sensitivity and health status in patients with chronic cough. Respir Med (2005) 1.22
Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease. Arthritis Rheum (2011) 1.22
Diagnosis of interstitial lung diseases. Mayo Clin Proc (2007) 1.19
Development and validity testing of an IPF-specific version of the St George's Respiratory Questionnaire. Thorax (2010) 1.14
Long-term reproducibility of Borg scale estimates of breathlessness during exercise. Clin Sci (Lond) (1991) 1.10
Clinical cough I: the urge-to-cough: a respiratory sensation. Handb Exp Pharmacol (2009) 1.10
Endpoints for clinical trials of sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis (2012) 1.07
MRC chronic Dyspnea Scale: Relationships with cardiopulmonary exercise testing and 6-minute walk test in idiopathic pulmonary fibrosis patients: a prospective study. BMC Pulm Med (2010) 1.06
The clinical significance of 5% change in vital capacity in patients with idiopathic pulmonary fibrosis: extended analysis of the pirfenidone trial. Respir Res (2011) 1.06
Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test. Ann Rheum Dis (2006) 1.05
The UCSD shortness of breath questionnaire has longitudinal construct validity in idiopathic pulmonary fibrosis. Respir Med (2012) 1.04
Dyspnea-12 is a valid and reliable measure of breathlessness in patients with interstitial lung disease. Chest (2010) 1.04
Dyspnea scales as a measure of health-related quality of life in patients with idiopathic pulmonary fibrosis. Med Sci Monit (2002) 1.02
Automated quantification of radiological patterns predicts survival in idiopathic pulmonary fibrosis. Eur Respir J (2013) 1.02
Cough and glottic-stop reflex sensitivity in health and disease. Chest (2005) 1.02
Clinical assessment of chronic cough severity. Pulm Pharmacol Ther (2006) 1.00
The Medical Research Council dyspnea scale in the estimation of disease severity in idiopathic pulmonary fibrosis. Respir Med (2004) 0.99
The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax (2012) 0.98
Development of the ATAQ-IPF: a tool to assess quality of life in IPF. Health Qual Life Outcomes (2010) 0.98
Quality of life and psychosocial aspects of cough. Lung (2007) 0.98
Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study. Eur Respir J (2012) 0.97
Quantitative stratification of diffuse parenchymal lung diseases. PLoS One (2014) 0.97
Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants. Thorax (2013) 0.97
Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial--results from the Scleroderma Lung Study. Rheumatology (Oxford) (2009) 0.97
Fibrosing interstitial pneumonia predicts survival in patients with rheumatoid arthritis-associated interstitial lung disease (RA-ILD). Respir Med (2013) 0.96
Cough predicts prognosis in idiopathic pulmonary fibrosis. Respirology (2011) 0.95
Reliability and validity of a Dutch version of the Leicester Cough Questionnaire. Cough (2007) 0.94
Fibrotic idiopathic interstitial pneumonias: HRCT findings that predict mortality. Eur Radiol (2011) 0.93
Assessing dyspnea and its impact on patients with connective tissue disease-related interstitial lung disease. Respir Med (2010) 0.93
Long-term follow-up CT scan evaluation in patients with pulmonary sarcoidosis. Chest (2005) 0.92
A practical approach to high-resolution CT of diffuse lung disease. Eur J Radiol (2013) 0.92
Objective cough frequency in Idiopathic Pulmonary Fibrosis. Cough (2010) 0.91
Quantitative texture-based assessment of one-year changes in fibrotic reticular patterns on HRCT in scleroderma lung disease treated with oral cyclophosphamide. Eur Radiol (2011) 0.89
Selection of clinically meaningful primary endpoints in phase 3 clinical trials in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med (2013) 0.89
A prospective global measure, the Punum Ladder, provides more valid assessments of quality of life than a retrospective transition measure. J Clin Epidemiol (2010) 0.89
Validation of the Cough Quality-of-Life Questionnaire in patients with idiopathic pulmonary fibrosis. Chest (2013) 0.89
Nonspecific interstitial pneumonia and idiopathic pulmonary fibrosis: changes in pattern and distribution of disease over time. Radiology (2008) 0.88
Patient-reported outcomes in idiopathic pulmonary fibrosis research. Chest (2012) 0.88
Screening for interstitial lung disease in systemic sclerosis: the diagnostic accuracy of HRCT image series with high increment and reduced number of slices. Ann Rheum Dis (2011) 0.85
Cyclooxygenase- and lipoxygenase-derived eicosanoids in bronchoalveolar lavage fluid from patients with scleroderma lung disease: an imbalance between proinflammatory and antiinflammatory lipid mediators. Arthritis Rheum (2005) 1.67
Clinical determinants of elevated systolic pulmonary artery pressure measured by transthoracic Doppler echocardiography in early systemic sclerosis. Clin Exp Rheumatol (2017) 0.75
Exercise pulmonary haemodynamics predict outcome in patients with systemic sclerosis. Eur Respir J (2016) 0.75